Journal of Crohn's and Colitis via PubMed Central
Systematic review
Feb 2020
For professionals
Reviews the evidence for 'treat to target', where treatment is adjusted not just to symptoms but to measured goals such as a healed bowel lining and normal blood or poo markers. It explains the idea behind the STRIDE targets and notes that firm proof that aiming for healing improves long-term outcomes was still emerging.
Topics
Monitoring
Research
Jargon explained
treat to target
mucosal healing
biomarker
STRIDE
New England Journal of Medicine
Study
Apr 2010
Patients and professionals
A landmark trial of 508 adults with moderate to severe Crohn's who had never had immunosuppressants or biologics. Infliximab and azathioprine together worked best: about 57% were in remission without steroids at 26 weeks, against 44% on infliximab alone and 30% on azathioprine alone. This is why many people starting infliximab are offered a second 'helper' drug alongside it.
Topics
Biologics and newer medicines
Immunosuppressants
Research
Jargon explained
combination therapy
steroid-free remission
mucosal healing
randomised controlled trial
The Lancet
Study
Dec 2017
Patients and professionals
CALM compared deciding treatment on symptoms alone with 'tight control', where treatment was stepped up if blood or poo tests (CRP and faecal calprotectin) showed inflammation even when people felt fine. After 48 weeks, 46% in the tight control group had a healed bowel lining compared with 30% in the symptom-only group. It is a cornerstone of the 'treat to target' approach.
Topics
Monitoring
Biologics and newer medicines
Research
Jargon explained
tight control
faecal calprotectin
CRP
mucosal healing
treat to target
Gastroenterology
Guideline
Apr 2021
For professionals
An international expert agreement on what 'treat to target' should aim for in IBD. Short-term goals are feeling better and getting blood and poo inflammation tests back to normal. Long-term goals include a healed bowel lining seen at endoscopy, no disability, a normal quality of life, and normal growth in children. Healing through the full bowel wall in Crohn's is not yet a formal target but is a sign of deeper remission.
Topics
Monitoring
Research
Medicines
Jargon explained
treat to target
endoscopic healing
transmural healing
biomarker
calprotectin
CRP
clinical remission
New England Journal of Medicine
Study
Jul 2024
Patients and professionals
A head-to-head trial in people whose Crohn's had not responded to, or who could not tolerate, anti-TNF drugs. Risankizumab (Skyrizi) was at least as good as ustekinumab (Stelara) for remission at 24 weeks and better at healing the bowel lining by 48 weeks. Side effects looked similar.
Topics
Biologics and newer medicines
Research
Jargon explained
non-inferiority
endoscopic remission
anti-TNF
The Lancet Gastroenterology & Hepatology
Study
Jan 2022
Patients and professionals
A small pilot trial of 44 adults with mild to moderate Crohn's who had not had biologics. The CDED, with or without supplement drinks, put more than half into remission at 6 weeks, and most of them were still in remission at 24 weeks. About a third had a healed bowel lining. The authors say a bigger trial is needed before firm conclusions.
Topics
Diet and nutrition
Jargon explained
pilot study
open-label
endoscopic remission
ECCO and ESPGHAN (J Crohns Colitis)
Guideline
Aug 2026
For professionals
The newest European guideline for children with Crohn's, agreed by 27 experts. Children at high risk of a difficult course should start an anti-TNF biologic first, with blood-level checks of the drug. For lower-risk children, a liquid-only diet (EEN) or the Crohn's Disease Exclusion Diet with partial liquid feeds are the preferred first treatments. Long-term goals include a healed bowel lining, normal growth and a good quality of life.
Topics
Children and young people
Diet and nutrition
Biologics and newer medicines
Monitoring
Jargon explained
anti-TNF
therapeutic drug monitoring
exclusive enteral nutrition
endoscopic remission
The Lancet
Study
May 2022
For professionals
The main international trial of risankizumab injections to keep Crohn's under control after a good response to drip treatment. More people who stayed on risankizumab remained in remission and had gut healing than those switched to placebo, and side effects were similar between groups.
Topics
Biologics and newer medicines
Research
Jargon explained
IL-23
maintenance
placebo
endoscopic response